FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2429622052> ?p ?o ?g. }

• W2429622052 abstract "Introduction The majority of studies from resource‐limited settings only report short‐term virological outcomes of patients on antiretroviral treatment (ART). We aim to describe the long‐term durability of first‐line ART and identify factors associated with long‐term virological outcomes. Methods At the Infectious Diseases Institute in Kampala, Uganda, 559 adult patients starting ART in 2004 were enrolled into a research cohort and monitored with viral load (VL) testing every six months for 10 years. We report the proportion and cumulative probability of 1) achieving virologic suppression (at least one VL <400 copies/ml); 2) experiencing virologic failure in patients who achieved suppression (two consecutive VLs >1000 copies/ml or one VL >5000, for those without a subsequent one); 3) treatment failure (not attaining virologic suppression or experiencing virologic failure). We used Cox regression methods to determine the characteristics associated with treatment failure. We included gender, baseline age, WHO stage, body mass index, CD4 count, propensity score for initial ART regimen, VL, time‐dependent CD4 count and adherence. Results Of the 559 patients enrolled, 472 (84.8%) had at least one VL (67 died, 13 were lost to follow‐up, 4 transferred, 2 had no VL available); 73.6% started on d4T/3TC/nevirapine and 26.4% on AZT/3TC/efavirenz. Patients in the two groups had similar characteristics, except for the higher proportion of patients in WHO Stage 3/4 and higher VL in the efavirenz‐based group. Four hundred thirty‐nine (93%) patients achieved virologic suppression with a cumulative probability of 0.94 (confidence interval (CI): 0.92–0.96); 74/439 (16.9%) experienced virologic failure with a cumulative probability of 0.18 (CI: 0.15–0.22). In the multivariate analysis, initial d4T/3TC/nevirapine regimen (hazard ratio (HR): 3.02; CI: 3.02 (1.66–5.44, p< 0.001)) and baseline VL ≥5 log10 copies/ml (HR: 2.29; CI: 1.29–4.04) were associated with treatment failures; patients of older age (HR: 0.87 per five‐year increase; CI: 0.77–0.99), with adherence >95% (HR: 0.04; CI: 0.02–0.11) and with higher time‐dependent CD4 count (HR: 0.94 per 50 cells/µl increase; CI: 0.92–0.99, p< 0.001) were less likely to experience treatment failure. Conclusions The long‐term virological outcomes from this cohort are promising and comparable to those from research‐rich settings. Our results provide further evidence that efavirenz is associated with better virological outcomes." @default.
• W2429622052 created "2016-06-24" @default.
• W2429622052 creator A5029557512 @default.
• W2429622052 creator A5042934531 @default.
• W2429622052 creator A5055903205 @default.
• W2429622052 creator A5067597194 @default.
• W2429622052 creator A5083823135 @default.
• W2429622052 creator A5091806880 @default.
• W2429622052 date "2016-01-01" @default.
• W2429622052 modified "2023-09-28" @default.
• W2429622052 title "First-line antiretroviral therapy durability in a 10-year cohort of naïve adults started on treatment in Uganda" @default.
• W2429622052 cites W1577924091 @default.
• W2429622052 cites W1579399611 @default.
• W2429622052 cites W1600314899 @default.
• W2429622052 cites W1607406129 @default.
• W2429622052 cites W1967825197 @default.
• W2429622052 cites W2000696170 @default.
• W2429622052 cites W2007607803 @default.
• W2429622052 cites W2013506230 @default.
• W2429622052 cites W2014040510 @default.
• W2429622052 cites W2014191329 @default.
• W2429622052 cites W2034930893 @default.
• W2429622052 cites W2038756830 @default.
• W2429622052 cites W2045871034 @default.
• W2429622052 cites W2053914237 @default.
• W2429622052 cites W2064309577 @default.
• W2429622052 cites W2067122390 @default.
• W2429622052 cites W2073706172 @default.
• W2429622052 cites W2073940149 @default.
• W2429622052 cites W2080436266 @default.
• W2429622052 cites W2090007886 @default.
• W2429622052 cites W2096563607 @default.
• W2429622052 cites W2110977476 @default.
• W2429622052 cites W2117659981 @default.
• W2429622052 cites W2120293408 @default.
• W2429622052 cites W2152505869 @default.
• W2429622052 cites W2163520820 @default.
• W2429622052 cites W2166949679 @default.
• W2429622052 cites W3196876339 @default.
• W2429622052 cites W89827783 @default.
• W2429622052 doi "https://doi.org/10.7448/ias.19.1.20773" @default.
• W2429622052 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4913145" @default.
• W2429622052 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27319742" @default.
• W2429622052 hasPublicationYear "2016" @default.
• W2429622052 type Work @default.
• W2429622052 sameAs 2429622052 @default.
• W2429622052 citedByCount "17" @default.
• W2429622052 countsByYear W24296220522017 @default.
• W2429622052 countsByYear W24296220522018 @default.
• W2429622052 countsByYear W24296220522019 @default.
• W2429622052 countsByYear W24296220522020 @default.
• W2429622052 countsByYear W24296220522021 @default.
• W2429622052 countsByYear W24296220522022 @default.
• W2429622052 countsByYear W24296220522023 @default.
• W2429622052 crossrefType "journal-article" @default.
• W2429622052 hasAuthorship W2429622052A5029557512 @default.
• W2429622052 hasAuthorship W2429622052A5042934531 @default.
• W2429622052 hasAuthorship W2429622052A5055903205 @default.
• W2429622052 hasAuthorship W2429622052A5067597194 @default.
• W2429622052 hasAuthorship W2429622052A5083823135 @default.
• W2429622052 hasAuthorship W2429622052A5091806880 @default.
• W2429622052 hasBestOaLocation W24296220521 @default.
• W2429622052 hasConcept C126322002 @default.
• W2429622052 hasConcept C142462285 @default.
• W2429622052 hasConcept C203014093 @default.
• W2429622052 hasConcept C2779130552 @default.
• W2429622052 hasConcept C2781413609 @default.
• W2429622052 hasConcept C2781432083 @default.
• W2429622052 hasConcept C2993143319 @default.
• W2429622052 hasConcept C3013748606 @default.
• W2429622052 hasConcept C50382708 @default.
• W2429622052 hasConcept C71924100 @default.
• W2429622052 hasConcept C72563966 @default.
• W2429622052 hasConcept C88879693 @default.
• W2429622052 hasConceptScore W2429622052C126322002 @default.
• W2429622052 hasConceptScore W2429622052C142462285 @default.
• W2429622052 hasConceptScore W2429622052C203014093 @default.
• W2429622052 hasConceptScore W2429622052C2779130552 @default.
• W2429622052 hasConceptScore W2429622052C2781413609 @default.
• W2429622052 hasConceptScore W2429622052C2781432083 @default.
• W2429622052 hasConceptScore W2429622052C2993143319 @default.
• W2429622052 hasConceptScore W2429622052C3013748606 @default.
• W2429622052 hasConceptScore W2429622052C50382708 @default.
• W2429622052 hasConceptScore W2429622052C71924100 @default.
• W2429622052 hasConceptScore W2429622052C72563966 @default.
• W2429622052 hasConceptScore W2429622052C88879693 @default.
• W2429622052 hasFunder F4320332161 @default.
• W2429622052 hasIssue "1" @default.
• W2429622052 hasLocation W24296220521 @default.
• W2429622052 hasLocation W24296220522 @default.
• W2429622052 hasLocation W24296220523 @default.
• W2429622052 hasLocation W24296220524 @default.
• W2429622052 hasOpenAccess W2429622052 @default.
• W2429622052 hasPrimaryLocation W24296220521 @default.
• W2429622052 hasRelatedWork W1991473739 @default.
• W2429622052 hasRelatedWork W2001009580 @default.
• W2429622052 hasRelatedWork W2127785206 @default.
• W2429622052 hasRelatedWork W2209580180 @default.
• W2429622052 hasRelatedWork W2928581063 @default.
• W2429622052 hasRelatedWork W2936279454 @default.

• next